MEDI-CAPS LIMITED

CIN: L70100MP1983PLC002231

MCL/SE/2025-2026 **Date: 12.11.2025**

Online filing at: **www.listing.bseindia.com**

To,
The General Manager
DCS-CRD
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street Fort, Mumbai – 400001(M.H.)

SUBJECT: OUTCOME OF BOARD MEETING HELD ON 12TH NOVEMBER, 2025 PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010)

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. Wednesday 12th November, 2025 has inter alia considered and approved the following businesses:

(1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter as well as half year ended on 30th September, 2025 along with Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report thereon.

(2) Other routine businesses with the permission of chair.

Further, a copy of aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL mode (Integrated Filing Financial) within prescribed time limit.

The aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be uploaded on the Company's website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit.

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 3.45 P.M.
You are requested to please take on record the same.

The above information will also be available on the website of the Company at www.medicaps.com.

Thanking You,

Yours Faithfully,

FOR MEDI-CAPS LIMITED

ALOK K GARG

Digitally signed by ALOK K GARG
Date: 2025.11.12 15:48:44 +05'30'

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

Encl.: Un-audited Standalone and Consolidated Financial Results, Statements of Assets and Liabilities & Cash flow along with limited review report for quarter as well as half year ended on 30th September, 2025.

RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
☎ Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

LIMITED REVIEW REPORT

Independent Auditor's Review Report for Quarter and Half Year Ended 30th September, 2025 on Unaudited Standalone Financial Results of Medi-Caps Limited (the "Company") Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying statement of unaudited standalone financial of MEDI-CAPS LIMITED ("the Company") for the quarter and half year ended 30th September 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

RAWKA & ASSOCIATES INDORE (M.P.) Chartered Accountants

CONCLUSION

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 12.11.2025
Place: Indore
UDIN: 25429040BMGSZS9903

For, Rawka & Associates
(Chartered Accountants)
FRN 021606C

RAWKA & ASSOCIATES
INDORE
(M.P)
Chartered Accountants

Venus Rawka
(Partner)
M. No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30.09.2025

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sept 30th, 2025	June 30th, 2025	Sept 30th, 2024	Sept 30th, 2025	Sept 30th, 2024	Mar 31st, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	**Revenue from Operation**						
	(a) Net sales	99.78	0.00	96.01	99.78	123.76	237.36
	(b) Other operating income	0.18	0.00	1.51	0.18	2.78	4.30
	Revenue from Operation	**99.96**	**0.00**	**97.52**	**99.96**	**126.54**	**241.66**
II	**Other Income**	0.97	31.33	9.66	32.30	20.38	56.25
III	**Total income (I+II)**	**100.93**	**31.33**	**107.18**	**132.26**	**146.92**	**297.91**
IV	**Expenses**						
	a) Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.15	0.00	0.17	0.15	0.22	0.45
	d) Employee benefits expense	45.90	45.67	45.38	91.57	90.61	181.05
	e) Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	f) Depreciation and amortisation expense	4.00	4.00	4.00	8.01	8.01	16.01
	g) Power Cost	0.37	0.58	0.08	0.94	0.15	0.49
	h) Freight Exp.	0.00	0.00	0.00	0.00	0.00	0.00
	i) Other expenses	21.86	20.83	13.01	42.68	36.55	71.41
	Total Expenses (IV)	**72.28**	**71.08**	**62.64**	**143.35**	**135.54**	**269.41**
V	**Profit/(Loss) before exceptional item & tax (III-IV)**	**28.65**	**-39.75**	**44.54**	**-11.09**	**11.38**	**28.50**
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	**Profit/ (Loss) before tax (V-VI)**	**28.65**	**-39.75**	**44.54**	**-11.09**	**11.38**	**28.50**
VIII	Tax expense						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	-25.56
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-1.45
	Total Tax Expenses	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**-27.01**
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
X	Profit (Loss) for the period from continuing operations (VII-VIII)	**28.65**	**-39.75**	**44.54**	**-11.09**	**11.38**	**55.51**
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
XIV	**Share of profit (loss) of associates and joint ventures accounted for using equity method**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
XV	Profit/(loss) for the period (X+XIII)	**28.65**	**-39.75**	**44.54**	**-11.09**	**11.38**	**55.51**
XVI	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	-11.83	54.25	47.32	42.42	93.78	29.95
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	**-11.83**	**54.25**	**47.32**	**42.42**	**93.78**	**29.95**
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	**16.82**	**14.50**	**91.86**	**31.33**	**105.16**	**85.46**
XVIII	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	0.00
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	0.00	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	5507.09	5487.39
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	0.23	-0.32	0.36	-0.09	0.09	0.45
	b) Diluted (Rs.)	0.23	-0.32	0.36	-0.09	0.09	0.45
XXIII	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	0.23	-0.32	0.36	-0.09	0.09	0.45
	b) Diluted (Rs.)	0.23	-0.32	0.36	-0.09	0.09	0.45

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2025

The standalone Statement of Assets & Liabilities is as under:			(Amount in Lacs)
	Particulars	**As at 30-09-2025**	**As at 31-03-2025**
		Unaudited	**Audited**
I.	**Assets**		
(1)	**Non-Current Assets**		
	(a) Property, Plant and Equipment	227.33	209.64
	(b) Capital work-in-progress	7.58	7.58
	(c) Goodwill	0.00	0.00
	(c) Investment Property	0.00	0.00
	(d) Financial Assets		
	(*i*) Investments	4390.47	4390.47
	(e) Other non-current assets	5.64	4.92
	Sub Total - Non-Current Assets	**4631.02**	**4612.61**
(2)	Current assets		
	(a) Inventories	2.56	2.71
	(b) Financial Assets		
	(*i*) Investments	1380.43	1297.99
	(*ii*) Trade receivables	255.39	366.40
	(iii). Cash and cash equivalents	0.43	5.24
	(*iv*) Bank balances other than (*iii*) above	0.00	0.00
	(c) Other current assets	559.10	517.71
	Sub Total - Current Assets	**2197.91**	**2190.05**
	Total Assets	**6828.93**	**6802.66**
II.	**EQUITY AND LIABILITIES**		
	EQUITY		
	(a) Equity Share Capital	1247.00	1247.00
	(b) Other Equity	5518.73	5487.39
	Sub Total - Equity	**6765.73**	**6734.39**
	LIABILITIES		
(1)	**Non-Current Liabilities**		
	(a) Financial Liabilities	0.00	0.00
	(b) Provisions	0.00	0.00
	(c) Deferred tax liabilities (Net)	41.45	41.45
	Sub Total - Non-Current Liabilities	**41.45**	**41.45**
(2)	**Current Liabilities**		
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	0.00	0.00
	(ii) Trade payables		
	a) total outstanding dues of micro enterprises and small enterprises; and		
	b) total outstanding dues of creditor other than micro enterprises and small enterprises;	5.11	4.03
	(*iii*) Other financial liabilities (other than those specified in item (*b*),	0.00	0.00
	(b) Other current liabilities	16.64	22.79
	(c) Provisions	0.00	0.00
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Sub Total - Current Liabilities	**21.75**	**26.82**
	Total Equity and Liabilities	**6828.93**	**6802.66**

DATE:12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435

Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED STANDALONE CASHFLOW STAEMEMT FOR THE HALF YEAR ENDED 30.09.2025

Amount in Lacs

PARTICULARS	30th Sept 2025	30th Sept 2024
	Unaudited	Unaudited
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items	(11.09)	11.38
Adjustment For:		
Depreciation	8.01	8.01
Dividend Income	0.00	0.00
Other Comprehensive Income	42.42	93.78
Profit/(Loss) from Discontinue operation	0.00	0.00
Operating Profit before Working Capital Change	**39.34**	**113.17**
Ajustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	111.01	61.56
(Increase)/ Decrease in Inventories	0.15	0.22
(Increase)/ Decrease in Loans & Advances	(42.11)	94.77
Increase/ (Decrease) in Current Liabilities & Prov.	(5.07)	(92.64)
Cash Generated from Working Capital	**63.98**	**63.91**
Cash generated from Operation	103.32	177.08
Net Income Tax Paid	0.00	0.00
Net cash Flow from Operating Activity	**103.32**	**177.08**
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments	(82.44)	(174.16)
Sale/(Purchase) of Fixed Assets	(25.69)	0.00
Dividend Received	0.00	0.00
Net Cash used in Investing Actvities	**(108.13)**	**(174.16)**
C. Cash Flow from Financial Activities		
Increase/ (Decrease) in Bank Borrowings	0.00	0.00
Net Cash Used in Financial Activities	**0.00**	**0.00**
Net Increase in Cash and Cash Equivalents (A+B+C)	**(4.81)**	**2.92**
Cash & Cash Equivalents at the Beginning of the year	5.24	4.54
Closing of the year	0.43	7.46
Increase in Cash and Cash Equivalents	**(4.81)**	**2.92**

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

RAWKA & ASSOCIATES
CHARTERED ACCOUNTANTS
412, Arcade Silver 56, 1, New Palasia, Indore - 1
Off. : 2541132, Mobile : 9039080380
E-mail : rawkaassociates@gmail.com,. cprawka@gmail.com

LIMITED REVIEW REPORT

Independent Auditor's Review Report for Quarter and Half Year Ended 30th September, 2025 on Unaudited Consolidated Financial Results of Medi-Caps Limited (the "Holding Company") Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
THE BOARD OF DIRECTORS OF
MEDI-CAPS LIMITED

SCOPE OF THE REVIEW

1. We have reviewed the accompanying Statement of the Consolidated Unaudited Financial Results ("the Statement") of Medi-Caps Limited ("the Holding Company") and its subsidiary (the Holding and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive profit for the quarter and half year ended September 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the SEBI Listing Regulations'), including relevant circular issued by the SEBI time to time.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and

RAWKA & ASSOCIATES INDORE (M.P.)

consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of its wholly-owned subsidiary **Medgel Private Limited**.

CONCLUSION

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the information and explanations given to us by the Holding Company's Management, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of SEBI- (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited interim financial results include the financial results of Medgel Private Limited (wholly owned subsidiary) which also have been reviewed by us and certified by the management, whose interim financial results include total assets Rs. 2566.22 Lakhs and reflect a total income of Rs.101.25 Lakhs, total net loss after tax of Rs. (210.80) Lakhs and total comprehensive income of Rs. (286.58) Lakhs for the quarter ended September 30, 2025, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements/ financial information, and financial results are not material to the group.

Our Conclusion on the statement in respect of matters stated in paragraph 6 above is not modified.

Date:.12-11-2025
Place: Indore
UDIN: 25429040BMGSZT6223

For, Rawka & Associates
Chartered Accountants
FRN 021606C

RAWKA & ASSOCIATES INDORE (M.P) Chartered Accountants

Venus Rawka
(Partner)
M. No. 429040

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com CIN: L70100MP1983PLC002231

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30.09.2025

(Amount in Lacs except EPS)

S.N.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Sept 30th, 2025	June 30th, 2025	Sept 30th, 2024	Sept 30th, 2025	Sept 30th, 2024	Mar 31st, 2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	**Revenue from Operation**						
	(a) Net sales	200.53	267.65	828.46	468.19	1443.02	2537.44
	(b) Other operating income	0.67	1.11	1.16	1.78	6.04	10.27
	Revenue from Operation	**201.20**	**268.76**	**829.62**	**469.97**	**1449.06**	**2547.71**
II	**Other Income**	152.83	33.49	28.62	186.32	43.20	272.95
III	**Total income (I+II)**	**354.03**	**302.25**	**858.24**	**656.29**	**1492.26**	**2820.66**
IV	**Expenses**						
	a) Cost of material consumed	128.00	169.19	215.33	297.19	605.95	1016.99
	b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-66.90	-10.35	177.88	-77.25	-6.57	48.17
	d) Employee benefits expense	185.26	186.06	187.87	371.32	359.64	758.36
	e) Finance costs	0.00	1.30	0.00	1.30	0.00	2.48
	f) Depreciation and amortisation expense	43.68	43.68	42.57	87.36	85.13	171.82
	g) Power Cost	36.48	53.47	51.70	89.95	94.93	167.72
	h) Freight Exp.	27.88	39.70	62.40	67.57	101.04	137.14
	i) Other expenses	181.78	168.39	89.26	350.17	276.56	602.09
	Total Expenses (IV)	**536.18**	**651.44**	**827.01**	**1187.61**	**1516.68**	**2904.77**
V	**Profit/(Loss) before exceptional item & tax (III-IV)**	**-182.15**	**-349.19**	**31.23**	**-531.32**	**-24.42**	**-84.11**
VI	Exceptional items	0.00	0.00	0.00	0.00		0.00
VII	**Profit/ (Loss) before tax (V-VI)**	**-182.15**	**-349.19**	**31.23**	**-531.32**	**-24.42**	**-84.11**
VIII	Tax expense						
	1) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	2) Earlier year (excess)/Short provision for tax written back	0.00	0.00	0.00	0.00	0.00	-25.56
	3) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-1.45
	Total Tax Expenses	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**-27.01**
IX	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
X	Profit (Loss) for the period from continuing operations (VII-VIII)	**-182.15**	**-349.19**	**31.23**	**-531.32**	**-24.42**	**-57.10**
XI	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) from Discontinued operations (after tax) (XI-XII)	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
XIV	**Share of profit (loss) of associates and joint ventures accounted for using equity method**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**	**0.00**
XV	Profit/(loss) for the period (X+XIII)	**-182.15**	**-349.19**	**31.23**	**-531.32**	**-24.42**	**-57.10**
XVI	Other comprehensive income						
	(a) (i) items that will not be reclassified to statement of profit & loss	-87.61	152.44	139.02	64.82	298.63	86.43
	(ii) Income tax on items that will not to be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	(b) (i) items that will be reclassified to statement of profit & loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax on items that will be reclassified to statement of P& L	0.00	0.00	0.00	0.00	0.00	0.00
	Other comprehensive income :	**-87.61**	**152.44**	**139.02**	**64.82**	**298.63**	**86.43**
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	**-269.76**	**-196.75**	**170.25**	**-466.50**	**274.21**	**29.33**
XVIII	Profit or Loss Attributable to						
	Profit or Loss Attributable to owners of Parents	**-182.15**	**-349.19**	**31.23**	**-531.32**	**-24.42**	**-57.10**
	Profit or Loss Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00
XIX	Total Comprehensive Income for the period Attributable to						
	Total Comprehensive Income for the period Attributable to owners of Parents	**-269.76**	**-196.75**	**170.25**	**-466.50**	**274.21**	**29.33**
	Total Comprehensive Income for the period Attributable to non-Controlling Interest	0.00	0.00	0.00	0.00	0.00	0.00

XX	Paid-up equity share capital of the company	1247.00	1247.00	1247.00	1247.00	1247.00	1247.00
XXI	Reserve Excluding Revaluation Reserve	0.00	0.00	0.00	0.00	11125.54	10880.66
XXII	Earnings per equity share (for continuing operation)						
	a) Basic (Rs.)	-1.46	-2.80	0.25	-4.26	-0.20	-0.46
	b) Diluted (Rs.)	-1.46	-2.80	0.25	-4.26	-0.20	-0.46
XXIII	Earnings per equity share (for discontinued operation)						
	a) Basic (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
	b) Diluted (Rs.)	0.00	0.00	0.00	0.00	0.00	0.00
XXIV	Earnings per equity share (for discontinued and continuing operation)						
	a) Basic (Rs.)	-1.46	-2.80	0.25	-4.26	-0.20	-0.46
	b) Diluted (Rs.)	-1.46	-2.80	0.25	-4.26	-0.20	-0.46

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2025

The Consolidated Statement of Assets & Liabilities is as under: **(Amount in Lacs)**

	Particulars	As at 30-09-2025	As at 31-03-2025
		Unaudited	Audited
I.	**Assets**		
(1)	**Non-Current Assets**		
	(a) Property, Plant and Equipment	2793.55	2795.84
	(b) Capital work-in-progress	7.58	7.58
	(c) Goodwill	2814.15	2814.15
	(c) Investment Property	0.00	0.00
	(d) Financial Assets		
	(*i*) Investments	1701.56	1542.23
	(e) Other non-current assets	44.43	38.72
	Sub Total - Non-Current Assets	**7361.27**	**7198.52**
(2)	Current assets		
	(a) Inventories	470.69	320.03
	(b) Financial Assets		
	(*i*) Investments	2494.10	2869.94
	(*ii*) Trade receivables	591.21	879.02
	(iii). Cash and cash equivalents	9.06	41.20
	(*iv*) Bank balances other than (*iii*) above	0.00	0.00
	(c) Other current assets	1199.93	1233.61
	Sub Total - Current Assets	**4764.99**	**5343.80**
	Total Assets	**12126.26**	**12542.32**
II.	**EQUITY AND LIABILITIES**		
	EQUITY		
	(a) Equity Share Capital	1247.00	1247.00
	(b) Other Equity	10414.16	10880.66
	Sub Total - Equity	**11661.16**	**12127.66**
	LIABILITIES		
(1)	**Non-Current Liabilities**		
	(a) Financial Liabilities	0.00	0.00
	(b) Provisions	61.94	63.34
	(c) Deferred tax liabilities (Net)	41.45	41.45
	Sub Total - Non-Current Liabilities	**103.39**	**104.79**
(2)	**Current Liabilities**		
	(a) Financial Liabilities	0.00	0.00
	(i) Borrowings	0.00	0.00
	(ii) Trade payables		
	a) total outstanding dues of micro enterprises and small enterprises; and		
	b) total outstanding dues of creditor other than micro enterprises and small enterprises;	167.57	158.10
	(*iii*) Other financial liabilities (other than those specified in item (*b*),	0.00	0.00
	(b) Other current liabilities	194.14	151.77
	(c) Provisions		
	(d) Current Tax Liabilities (Net)	0.00	0.00
	Sub Total - Current Liabilities	**361.71**	**309.87**
	Total Equity and Liabilities	**12126.26**	**12542.32**

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI CAPS LIMITED
REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

Unaudited Consolidated Cash Flow Statement for the half year ended 30th Sept 2025

Amount in Lacs

PARTICULARS	**30th Sept 2025**	**30th Sept 2024**
	Unaudited	**Unaudited**
A. Cash Flow from Operating Activities		
Net Profit before Tax & Extraordinary Items	**-531.32**	**-24.42**
Adjustment For:		
Depreciation	87.36	85.13
Dividend Income	-0.35	0.00
Other Comprehensive Income	64.82	298.63
Loss from discontinue Operation	0.00	0.00
Operating Profit before Working Capital Change	**-379.49**	**359.34**
Ajustment for Working Capital		
(Increase)/ Decrease in Sundry Debtors	287.81	264.44
(Increase)/ Decrease in Inventories	-150.66	75.40
(Increase)/ Decrease in Loans & Advances	32.96	-35.82
Increase/(Decrease) in Current Liabilities & Provision	50.43	-110.98
Cash Generated from Working Capital	**220.54**	**193.04**
Cash generated from Operation	-158.95	552.38
Income Tax for the year	0.00	0.00
Net cash Flow from Operating Activity	**-158.95**	**552.38**
B. Cash Flow from Investing Activities		
Sale/(Purchase) of Investments	211.52	-483.15
Purachse of Fixed Assets	-85.06	-3.47
Dividend Received	0.35	0.00
Net Cash used in Investing Actvities	**126.81**	**-486.62**
C. Cash Flow from Financial Activities		
Increase in Short term Bank Borrowings	0.00	0.00
Proceeds from Long Term Borrowings	0.00	0.00
Net Cash Used in Financial Activities	**0.00**	**0.00**
Net Increase in Cash and Cash Equivalents (A+B+C)	**-32.14**	**65.76**
Cash & Cash Equivalents at the		
Beginning of the year	41.20	32.14
Closing of the year	9.06	97.90
Increase in Cash and Cash Equivalents	**-32.14**	**65.76**

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

MEDI-CAPS LIMITED

REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P.) - 452001 PHONE: 0731-4028148 FAX: 0731-4041435
Website: www.medicaps.com **Email:** investors@medicaps.com **CIN:** L70100MP1983PLC002231

UNAUDITED CONSOLIDATED SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED FOR THE QUARTER/HALF YEAR ENDED 30.09.2025

(Amount in Lacs)

S.No.	Segment Revenue	Quarter Ended			Half Year Ended		Year Ended
		Sept 30th, 2025	June 30th, 2025	Sept 30th, 2024	Sept 30th, 2025	Sept 30th, 2024	Mar 31st, 2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Segment Revenue**						
	Pharma Division	101.24	268.76	732.10	370.01	1322.52	2306.05
	Real Estate Division	99.96	0.00	97.52	99.96	126.54	241.66
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Net Sale/Income From Operations	**201.20**	**268.76**	**829.62**	**469.97**	**1449.06**	**2547.71**
2	**Segment Results (Profit) (+)/ Loss (-) before tax and Interest**						
	Pharma Division	-210.80	-308.14	-13.32	-518.93	-35.80	-110.13
	Real Estate Division	28.65	-39.75	44.54	-11.09	11.38	28.50
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total	**-182.15**	**-347.89**	**31.23**	**-530.02**	**-24.42**	**-81.63**
	Interest Income	0.00	0.00	0.00	0.00	0.00	0.00
	Interest Expenses	0.00	1.30	0.00	1.30	0.00	2.48
	Other Unallocable Expenditure net off	0.00	0.00	0.00	0.00	0.00	0.00
	Unallocable Income	0.00	0.00	0.00	0.00	0.00	0.00
	Profit Before Tax	**-182.15**	**-349.19**	**31.23**	**-531.32**	**-24.42**	**-84.11**
3	**Capital Employed**						
	Segment Assets (A)						
	Pharma Division	5297.33	5491.74	6069.96	5297.33	6069.96	5739.66
	Real Estate Division	6828.93	6810.76	6821.74	6828.93	6821.74	6802.66
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (A)	**12126.26**	**12302.50**	**12891.70**	**12126.26**	**12891.70**	**12542.32**
	Segment Liabilities (B)						
	Pharma Division	401.90	309.72	451.52	401.90	451.52	346.40
	Real Estate Division	63.20	61.86	67.65	63.20	67.65	68.27
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total (B)	**465.10**	**371.58**	**519.17**	**465.10**	**519.17**	**414.67**
4	**Total Capital Employed (Segment Assets-Segment Liabilities)**						
	Pharma Division	4895.43	5182.02	5618.44	4895.43	5618.44	5393.27
	Real Estate Division	6765.73	6748.90	6754.09	6765.73	6754.09	6734.39
	Other	0.00	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	**11661.16**	**11930.92**	**12372.53**	**11661.16**	**12372.53**	**12127.66**

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of board of directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321

NOTES:

1. The above standalone and consolidated unaudited financial results for the Quarter and half year ended September 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 12, 2025. The above results have been reviewed by Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised the necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2. This above standalone and consolidated unaudited financial results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above consolidated results included the results of the wholly owned subsidiary company i.e. Medgel Private Limited.

4. The Company has two reportable segments for the Consolidated Financial Statements which consists of the Pharma division and Real Estate division in accordance with Ind AS-108 Operating Segment and the same is enclosed with this result.

5. During this quarter the Company has generated revenue of Rs. 99.78 Lacs from sale of shops at Medi-caps Business Park.

6. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or re-casted wherever found necessary.

7. The aforesaid unaudited financial Results will be uploaded on the Company's website www.medicaps.com and will also be available on the websites of the Stock exchange i.e. www.bseindia.com for the benefit of shareholders and investors. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available, will be published in English and Hindi Newspapers with in prescribed time limit.

DATE: 12.11.2025
PLACE: INDORE

For and on behalf of the Board of Directors of
MEDI-CAPS LIMITED

ALOK K GARG
MANAGING DIRECTOR
DIN: 00274321